.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The discovery of ferroptosis has fundamentally shifted our understanding of heart health. Ferroptosis in Cardiovascular Diseases is a regulated cell death process that iron accumulation and lipid peroxidation drive. Consequently, it plays a critical role in various conditions like heart failure and atherosclerosis. This unique mechanism differs from apoptosis or necrosis. Therefore, it offers a fresh target for diagnostic and therapeutic innovation.
Researchers identify iron homeostasis and lipid peroxidation as the two core pillars of this process. Specifically, the accumulation of free iron triggers the Fenton reaction. This reaction produces reactive oxygen species that damage cell membranes. Meanwhile, antioxidant systems like GPX4 work to neutralize these threats. However, when these defenses fail, cells undergo irreversible damage.
Ferroptosis contributes significantly to myocardial ischemia-reperfusion injury and heart failure progression. Furthermore, it drives atherosclerotic plaque instability by promoting inflammation and foam cell formation. In cases of diabetic cardiomyopathy, high glucose levels often trigger this pathway. Thus, clinicians must recognize its broad impact on cardiac remodeling.
Accurate diagnosis requires validated biomarkers. Currently, scientists are evaluating circulating lipid peroxidation products and iron metabolism indices. For example, levels of malondialdehyde (MDA) and glutathione peroxidase 4 (GPX4) serve as potential indicators. Additionally, advanced imaging surrogates may soon help track these processes in real-time.
Modulating ferroptosis offers a promising avenue for treatment. New strategies range from iron chelation to GPX4-modulating agents. Moreover, nanomedicine-based delivery platforms could improve the safety profiles of these drugs. While clinical translation remains ongoing, these advancements represent a significant leap forward.
Ferroptosis is uniquely dependent on iron and involves the catastrophic accumulation of lipid peroxides, unlike the caspase-driven process of apoptosis.
Yes, preclinical studies suggest that iron chelation can reduce myocardial damage by preventing the Fenton reaction and subsequent oxidative stress.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Professional medical guidance should always be sought for the diagnosis and treatment of any health condition. Refer to the latest local and national guidelines for clinical practice.
References
Yu S et al. Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target. Mol Biomed. 2026 Mar 08. doi: undefined. PMID: 41795043.
Zhao Y, Linkermann A, Takahashi M, Li Q, Zhou X. Ferroptosis in cardiovascular disease: regulatory mechanisms and therapeutic implications. Eur Heart J. 2025 Sep 1;46(33):3247-3260. doi: 10.1093/eurheartj/ehaf374. PMID: 38831521.
Guo S, Liu J, Hua J, Ding L, Chen Q. Ferroptosis: The Pivotal Link in Cardiovascular Diseases Pathogenesis and Therapy. Int J Gen Med. 2025 Dec 19;18:7675-7697. doi: 10.2147/IJGM.S581227. PMID: 41450531.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Explore the molecular mechanisms of ferroptosis in heart disease and its potential as a therapeutic target for heart failure and atherosclerosis....
7 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
